{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:17:36Z","timestamp":1790799456820,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003032","name":"Association Nationale de la Recherche et de la Technologie","doi-asserted-by":"publisher","award":["2021\/1440"],"award-info":[{"award-number":["2021\/1440"]}],"id":[{"id":"10.13039\/501100003032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00228-023-03587-0","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:02:25Z","timestamp":1698501745000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm"],"prefix":"10.1007","volume":"80","author":[{"given":"K\u00e9vin","family":"Koloskoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Chambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0695","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"issue":"22","key":"3587_CR1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC (2011) Systemic Lupus Erythematosus. N Engl J Med 365(22):2110\u20132121","journal-title":"N Engl J Med"},{"issue":"6","key":"3587_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3587_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F et al (2021) Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 43(2):150\u2013200","journal-title":"Ther Drug Monit"},{"issue":"2","key":"3587_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00467-020-04733-x","volume":"36","author":"A Godron-Dubrasquet","year":"2021","unstructured":"Godron-Dubrasquet A, Woillard JB, Decramer S, Fila M, Guigonis V, Tellier S et al (2021) Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis. Pediatr Nephrol Berl Ger 36(2):341\u2013347","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"5","key":"3587_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40262-017-0593-6","volume":"57","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Ensom MHH (2018) Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet 57(5):547\u2013558","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3587_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40262-018-0687-9","volume":"57","author":"JB Woillard","year":"2018","unstructured":"Woillard JB, Debord J, Marquet P (2018) Comment on \u201cPopulation pharmacokinetics of mycophenolic acid: an update.\u201d Clin Pharmacokinet 57(9):1211\u20131213","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3587_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2010.10.017","volume":"63","author":"A Pr\u00e9maud","year":"2011","unstructured":"Pr\u00e9maud A, Weber LT, T\u00f6nshoff B, Armstrong VW, Oellerich M, Urien S et al (2011) Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res 63(3):216\u2013224","journal-title":"Pharmacol Res"},{"issue":"9","key":"3587_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40262-023-01280-0","volume":"62","author":"Y Rong","year":"2023","unstructured":"Rong Y, Wichart J, Hamiwka L, Kiang TKL (2023) Significant effects of renal function on mycophenolic acid total clearance in pediatric kidney transplant recipients with population pharmacokinetic modeling. Clin Pharmacokinet 62(9):1289\u20131303","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3587_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/00498254.2016.1214885","volume":"47","author":"XX Wang","year":"2017","unstructured":"Wang XX, Liu W, Zheng T, Park JM, Smith DE, Feng MR (2017) Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. Xenobiotica Fate Foreign Compd Biol Syst 47(8):697\u2013704","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"issue":"11","key":"3587_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1177\/0091270009357429","volume":"50","author":"W Zhao","year":"2010","unstructured":"Zhao W, Fakhoury M, Desch\u00eanes G, Roussey G, Brochard K, Niaudet P et al (2010) Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 50(11):1280\u20131291","journal-title":"J Clin Pharmacol"},{"key":"3587_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","volume":"99","author":"JB Woillard","year":"2015","unstructured":"Woillard JB, Saint-Marcoux F, Monchaud C, Youdar\u00e8ne R, Pouche L, Marquet P (2015) Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacol Res 99:308\u2013315","journal-title":"Pharmacol Res"},{"issue":"8","key":"3587_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","volume":"44","author":"A Pr\u00e9maud","year":"2005","unstructured":"Pr\u00e9maud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y et al (2005) A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 44(8):837\u2013847","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3587_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","volume":"27","author":"A Pr\u00e9maud","year":"2005","unstructured":"Pr\u00e9maud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G et al (2005) Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 27(3):354\u2013361","journal-title":"Ther Drug Monit"},{"issue":"10","key":"3587_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2165\/11317140-000000000-00000","volume":"48","author":"F Saint-Marcoux","year":"2009","unstructured":"Saint-Marcoux F, Royer B, Debord J, Larosa F, Legrand F, Deconinck E et al (2009) Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet 48(10):667\u2013675","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3587_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00003088-200847040-00005","volume":"47","author":"N Zahr","year":"2008","unstructured":"Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P et al (2008) Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 47(4):277\u2013284","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3587_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.phrs.2011.01.009","volume":"63","author":"F Saint-Marcoux","year":"2011","unstructured":"Saint-Marcoux F, Guigonis V, Decramer S, Gandia P, Ranchin B, Parant F et al (2011) Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res 63(5):423\u2013431","journal-title":"Pharmacol Res"},{"issue":"12","key":"3587_CR17","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1007\/s11095-006-9116-0","volume":"23","author":"JH Proost","year":"2006","unstructured":"Proost JH, Eleveld DJ (2006) Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res 23(12):2748\u20132759","journal-title":"Pharm Res"},{"issue":"7","key":"3587_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00003-22","volume":"66","author":"R Abolhassani-Chimeh","year":"2022","unstructured":"Abolhassani-Chimeh R, Akkerman OW, Saktiawati AMI, Punt NC, Bolhuis MS, Subronto YW et al (2022) Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis. Antimicrob Agents Chemother 66(7):e0000322","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"3587_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/03602538409015063","volume":"15","author":"LB Sheiner","year":"1984","unstructured":"Sheiner LB (1984) The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15(1\u20132):153\u2013171","journal-title":"Drug Metab Rev"},{"issue":"1\u20132","key":"3587_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/03602538409015064","volume":"15","author":"SL Beal","year":"1984","unstructured":"Beal SL (1984) Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 15(1\u20132):173\u2013193","journal-title":"Drug Metab Rev"},{"issue":"1","key":"3587_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1214\/aos\/1018031103","volume":"27","author":"B Delyon","year":"1999","unstructured":"Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann Stat 27(1):94\u2013128","journal-title":"Ann Stat"},{"issue":"4","key":"3587_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10928-016-9476-y","volume":"43","author":"X Liu","year":"2016","unstructured":"Liu X, Wang Y (2016) Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 43(4):359\u2013370","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"3587_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bcp.12392","volume":"78","author":"JB Woillard","year":"2014","unstructured":"Woillard JB, Bader-Meunier B, Salomon R, Ranchin B, Decramer S, Fischbach M et al (2014) Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. Br J Clin Pharmacol 78(4):867\u2013876","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3587_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00228-022-03295-1","volume":"78","author":"Q Beaulieu","year":"2022","unstructured":"Beaulieu Q, Zhang D, Melki I, Baudouin V, Goldwirst L, Woillard JB et al (2022) Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus. Eur J Clin Pharmacol 78(6):1003\u20131010","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3587_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-200140050-00004","volume":"40","author":"J Debord","year":"2001","unstructured":"Debord J, Risco E, Harel M, Le Meur Y, B\u00fcchler M, Lach\u00e2tre G et al (2001) Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 40(5):375\u2013382","journal-title":"Clin Pharmacokinet"},{"key":"3587_CR26","unstructured":"Monolix (2019) Monolix 2019 User Guide"},{"issue":"1","key":"3587_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40780-022-00271-w","volume":"9","author":"T Mizaki","year":"2023","unstructured":"Mizaki T, Nobata H, Banno S, Yamaguchi M, Kinashi H, Iwagaitsu S et al (2023) Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. J Pharm Health Care Sci 9(1):1","journal-title":"J Pharm Health Care Sci"},{"issue":"2","key":"3587_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jcph.1650","volume":"62","author":"S Goutelle","year":"2022","unstructured":"Goutelle S, Woillard JB, Neely M, Yamada W, Bourguignon L (2022) Nonparametric methods in population pharmacokinetics. J Clin Pharmacol 62(2):142\u2013157","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3587_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2125.2011.04140.x","volume":"73","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Sagcal-Gironella ACP, Fukuda T, Brunner HI, Vinks AA (2012) Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol 73(5):727\u2013740","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3587_CR30","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/bcp.14590","volume":"87","author":"Y Rong","year":"2021","unstructured":"Rong Y, Jun H, Kiang TKL (2021) Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol 87(4):1730\u20131757","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3587_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40262-020-00959-y","volume":"60","author":"P Marquet","year":"2021","unstructured":"Marquet P, Dest\u00e8re A, Monchaud C, R\u00e9rolle JP, Buchler M, Mazouz H et al (2021) Clinical pharmacokinetics and Bayesian estimators for the individual dose adjustment of a generic formulation of tacrolimus in adult kidney transplant recipients. Clin Pharmacokinet 60(5):611\u2013622","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3587_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/00003088-200645040-00003","volume":"45","author":"A Bustad","year":"2006","unstructured":"Bustad A, Terziivanov D, Leary R, Port R, Schumitzky A, Jelliffe R (2006) Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 45(4):365\u2013383","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3587_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10601339509079574","volume":"12","author":"AA Carter","year":"1995","unstructured":"Carter AA, Rosenbaum SE, Dudley MN (1995) Review of methods in population pharmacokinetics. Clin Res Regul Aff 12(1):1\u201321","journal-title":"Clin Res Regul Aff"},{"key":"3587_CR34","doi-asserted-by":"crossref","unstructured":"Jelliffe R, Schumitzky A, Bustad A, Van Guilder M, Wang X, Leary R (2004) Population pharmacokinetic and pharmacodynamic modeling. In: Krishna R,. Applications of pharmacokinetic principles in drug development. Boston, MA: Springer US 373\u2011404","DOI":"10.1007\/978-1-4419-9216-1_12"},{"key":"3587_CR35","doi-asserted-by":"crossref","unstructured":"Sheiner LB, Beal SL (1980) Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8(6):553\u201171","DOI":"10.1007\/BF01060053"},{"issue":"5","key":"3587_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B et al (2007) Overview of model-building strategies in population PK\/PD analyses: 2002\u20132004 literature survey. Br J Clin Pharmacol 64(5):603\u2013612","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3587_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1208\/s12248-010-9238-5","volume":"13","author":"RM Savic","year":"2011","unstructured":"Savic RM, Mentr\u00e9 F, Lavielle M (2011) Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics\u2013pharmacodynamics. AAPS J 13(1):44\u201353","journal-title":"AAPS J"},{"issue":"4","key":"3587_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10928-009-9127-7","volume":"36","author":"R Savic","year":"2009","unstructured":"Savic R, Lavielle M (2009) Performance in population models for count data, part II: a new SAEM algorithm. J Pharmacokinet Pharmacodyn 36(4):367\u2013379","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"3587_CR39","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1080\/00949655.2013.878938","volume":"85","author":"C Mbogning","year":"2015","unstructured":"Mbogning C, Bleakley K, Lavielle M (2015) Joint modelling of longitudinal and repeated time-to-event data using nonlinear mixed-effects models and the stochastic approximation expectation\u2013maximization algorithm. J Stat Comput Simul 85(8):1512\u20131528","journal-title":"J Stat Comput Simul"},{"issue":"5","key":"3587_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11222-013-9396-2","volume":"24","author":"M Lavielle","year":"2014","unstructured":"Lavielle M, Mbogning C (2014) An improved SAEM algorithm for maximum likelihood estimation in mixtures of non linear mixed effects models. Stat Comput 24(5):693\u2013707","journal-title":"Stat Comput"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03587-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:02:46Z","timestamp":1704870166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03587-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3587"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03587-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Specific approval of an ethics committee is not needed for a non-interventional study based on anonymized data of authorized collections and written parental consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}